CD8A and neoplasm: PD-1-laIL-2, with a higher affinity to PD-1+CD8+ T cells than to peripheral Treg cells, was able to amplify the dysfunctional tumor-specific CD8+ T cells potently, thus overcoming tumor resistance to ICB (111).